Synucleins: Are they two-edged swords?

Journal of Neuroscience Research

Volumn 91, Issue 2, 2013, Pages 161-166

  Surguchov, Andrei ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

synuclein; Neurodegenerative diseases; Parkinson's disease; Posttranslational modifications; Protein folding; Synucleins

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; GAMMA SYNUCLEIN; SYNUCLEIN;

AMINO TERMINAL SEQUENCE; BREAST CANCER; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; DEGENERATIVE DISEASE; GENE MUTATION; GENETIC LINKAGE; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROCESSING; SHORT SURVEY;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PROTEIN STRUCTURE, TERTIARY; SYNUCLEINS;

EID: 84870953899     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23149     Document Type: Short Survey

References (69)

1. Abeliovich A, Schmitz Y, Fariñas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. 2001. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239-252.
2. Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM. 2007. Gamma-synuclein and the progression of cancer. FASEB J 21: 3419-3430.
3. Angot E, Brundin P. 2009. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. Parkinsonism Rel Disord Suppl 3: S143-S147.
4. Angot E, Steiner JA, Lema Tomé CM, Ekström P, Mattsson B, Björklund A, Brundin P. 2012. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 7: e39465.
5. Anwar S, Peters O, Millership S, Ninkina N, Doig N, Connor-Robson N, Threlfell S, Kooner G, Deacon RM, Bannerman DM, Bolam JP, Chandra SS, Cragg SJ, Wade-Martins R, Buchman VL. 2011. Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci 31: 7264-7274.
6. Bartels T, Choi JG, Selkoe DJ. 2011. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477: 107-110.
7. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
8. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. 2008. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci 9: 741-745.
9. Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC. 2010. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329: 1663-1667.
10. Cabeza-Arvelaiz Y, Fleming SM, Richter F, Masliah E, Chesselet MF, Schiestl RH. 2011. Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Mol Neurodegener 13: 83-99.
11. Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC. 2005. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123: 383-396.
12. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destée A. 2004. α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169.
13. Chen L, Feany MB. 2005. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8: 657-663.
14. 46K. Neurotoxicology 32: 857-863.
15. Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B. 2009. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem 111: 192-203.
16. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. 2009. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106: 13010-13015.
17. Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N, Eliezer D, Moore DJ, Schneider B, Aebischer P, El-Agnaf OM, Masliah E, Lashuel HA. 2012. α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287: 15345-15364.
18. Galvin JE, Uryu K, Lee VM, Trojanowski JQ. 1999. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein. Proc Natl Acad Sci U S A 96: 13450-13455.
19. Galvin JE, Lee V, Trojanowski JQ. 2001. Synucleinopathies: clinical and pathological implications. Arch Neurol 58: 186-190.
20. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. 2008. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28: 7687-7698.
21. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM. 2003. Initiation and synergistic fibrillization of tau and α-synuclein. Science 300: 636-640.
22. Goedert M, Clavaguera F, Tolnay M. 2010. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 33: 317-325.
23. Greten-Harrison B, Polydoro M, Morimoto-Tomita M, Diao L, Williams AM, Nie EH, Makani S, Tian N, Castillo PE, Buchman VL, Chandra SS. 2010. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A 107: 19573-19578.
24. Hasegawa M. 2011. "Protein cancers" hypothesis for neurodegenerative diseases. Rinsho Shinkeigaku 51: 1101-1104.
25. Hashimoto M, Rockenstein E, Mallory M, Masliah E. 2001. β-Synuclein inhibits α-synuclein aggregation. Neuron 32: 213-223.
26. Hashimoto M, Hsu LJ, Rockenstein E, Takenouchi T, Mallory M, Masliah E. 2002. β-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase signaling pathway. J Biol Chem 277: 11465-11472.
27. Hashimoto M, Rockenstein E, Crews L, Masliah E. 2004. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromol Med 4: 21-36.
28. Jakes R, Spillantini MG, Goedert M. 1994. Identification of two distinct synucleins from human brain. FEBS Lett 345: 27-32.
29. Jensen PJ, Alter BJ, O'Malley KL. 2003. Alpha-synuclein protects naive but not dbcAMP-treated dopaminergic cell types from 1-methyl-4-phenylpyridinium toxicity. J Neurochem 86: 196-209.
30. Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, Joseph BK, Rosen C, Shi YE. 1997. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 57: 759-764.
31. Jiang Y, Liu YE, Goldberg ID, Shi YE. 2004. Gamma synuclein, a novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor alpha signaling and mammary tumorigenesis. Cancer Res 64: 4539-4546.
32. Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, Adame A, Masliah E. 2010. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol 221: 267-274.
33. 30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
34. Leng Y, Chuang DM. 2006. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 26: 7502-7512.
35. Lu A, Gupta A, Li C, Ahlborn TE, Ma Y, Shi EY, Liu J. 2001. Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences. Oncogene 20: 5173-5185.
36. Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA. 2003. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23: 3095-3099.
37. Maroteaux L, Campanelli JT, Scheller RH. 1988. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8: 2804-2815.
38. Maurage CA, Ruchoux MM, de Vos R, Surguchov A, Destee A. 2003. Retinal involvement in dementia with Lewy bodies: a clue to hallucinations? Ann Neurol 54: 542-547.
39. Monti B, Polazzi E, Batti L, Crochemore C, Virgili M, Contestabile A. 2007. Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death. J Neurochem 103: 518-530.
40. Mouradian MM. 2012. MicroRNAs in Parkinson's disease. Neurobiol Dis 46: 279-284.
41. Nakajo S, Tsukada K, Omata K, Nakamura Y, Nakaya K. 1993. A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur J Biochem 217: 1057-1063.
42. Nguyen JV, Soto I, Kim KY, Bushong EA, Oglesby E, Valiente-Soriano FJ, Yang Z, Davis CH, Bedont JL, Son JL, Wei JO, Buchman VL, Zack DJ, Vidal-Sanz M, Ellisman MH, Marsh-Armstrong N. 2011. Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. Proc Natl Acad Sci U S A 108: 1176-1181.
43. Ninkina NN, Alimova-Kost MV, Paterson JW, Delaney L, Cohen BB, Imreh S, Gnuchev NV, Davies AM, Buchman VL. 1998. Organization, expression and polymorphism of the human persyn. Hum Mol Genet 7: 1417-1424.
44. Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL. 2009. Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet 18: 1779-1794.
45. Olanow CW, Prusiner SB. 2009. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A 106: 12571-12572.
46. Ono K, Takahashi R, Ikeda T, Yamada M. 2012. Cross-seeding effects of amyloid β-protein and α-synuclein. J Neurochem [Jun 26 E-pub ahead of print; doi: 10.1111/j.1471-4159.2012.07847].
47. Polymenidou M, Cleveland DW. 2012. Prion-like spread of protein aggregates in neurodegeneration. J Exp Med 209: 889-893.
48. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
49. Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, Bohn MC. 2006. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 198: 382-390.
50. Seo JH, Rah JC, Choi SH, Shin JK, Min K, Kim HS, Park CH, Kim S, Kim EM, Lee SH, Lee S, Suh SW, Suh YH. 2002. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J 16: 1826-1828.
51. Sidhu A, Wersinger C, Moussa CE, Vernier P. 2004. The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann N Y Acad Sci 1035: 250-270.
52. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. α-Synuclein locus triplication causes Parkinson's disease. Science 302: 841-843.
53. Smith WW, Margolis RL, Li X, Troncoso JC, Lee MK, Dawson VL, Dawson TM, Iwatsubo T, Ross CA. 2005. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci 25: 5544-5552.
54. Snyder H, Mensah K, Hsu C, Hashimoto M, Surgucheva IG, Festoff B, Surguchov A, Masliah E, Matouschek A, Wolozin B. 2005. Beta-synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein. J Biol Chem 280: 7562-7569.
55. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
56. St. Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ. 2007. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of α-synuclein in mouse substantia nigra. J Neurochem 100: 1449-1457.
57. Surgucheva I, McMahan B, Ahmed F, Tomarev S, Wax MB, Surguchov A. 2002. Synucleins in glaucoma: implication of γ-synuclein in glaucomatous alterations in the optic nerve. J Neurosci Res 68: 97-106.
58. Surgucheva I, Sharov VS, Surguchov A. 2012. γ-Synuclein: seeding of α-synuclein aggregation and transmission between cells. Biochemistry [May 23 E-pub ahead of print; http://dx.doi.org/10.1021/bi300478w].
59. Surguchov A. 1987. Common genes for mitochondrial and cytoplasmic proteins. Trends Biochem Sci 12: 335-339.
60. Surguchov A. 2008. Molecular and cellular biology of synucleins. Int Rev Cell Mol Biol 270: 225-317.
61. Surguchov A, Sudarickov AB, Telckov MV, Smirnov VN, Ter-Avanesyan MD, Inge-Vechtomov SG. 1983. Relationship between cytoplasmic and mitochondrial apparatus of protein synthesis in yeast Saccharomyces cerevisiae. Mol Gen Genet 189: 172-174.
62. Surguchov A, Surgucheva I, Solessio E, Baehr W. 1999. Synoretin-a new protein belonging to the synuclein family. Mol Cell Neurosci 13: 95-103.
63. Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Yuan JX, Masliah E. 2007. Dynamics of α-synuclein aggregation and inhibition of pore-like oligomer development by α-synuclein. FEBS J 274: 1862-1877.
64. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E. 2008. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One 3: e3135.
65. Uversky VN. 2003. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn 21: 211-234.
66. 2 in a human neuroblastoma divided cell line transfected with alpha-synuclein and its familial Parkinson's disease-linked mutants. Neurosci Lett 342: 124-128.
67. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. 1999. α-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274: 19509-19512.
68. Zakharov SD, Hulleman JD, Dutseva EA, Antonenko YN, Rochet JC, Cramer WA. 2007. Helical alpha-synuclein forms highly conductive ion channels. Biochemistry 46: 14369-14379.
69. 46K, of α-synuclein causes Parkinson and LB dementia. Ann Neurol 55: 164-173.